Table 2.
Cohort demographic analysis of groups formed according to FMR1 genotypes
| All patients | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Demographics | high/high | high/low | high/normal | normal/normal | normal/low | low/low | p value | ||||||
| n | (P25-P75) | n | (P25-P75) | n | (P25-P75) | n | (P25-P75) | n | (P25-P75) | n | (P25-P75) | ||
| Agea | 2 | 34 ± 5.6 | 3 | 28.6 ± 1.1 | 25 | 35.4 ± 4.4 | 123 | 35.7 ± 4.5 | 65 | 35.9 ± 4.7 | 8 | 36.3 ± 3.2 | 0.163 |
| AFC | 2 | 6 (6–6) | 0 | – | 18 | 3 (1.8–7.1) | 62 | 5.75 (3–9.12) | 38 | 5 (3–6.1) | 3 | 5.5 (3.5–10) | 0.239 |
| FSH | 2 | 9.5 (6.6–12.4) | 2 | 7.3 (6.9–7.7) | 23 | 8.3 (6.1–10.9) | 110 | 7.1 (5.7–8.7) | 56 | 7.8 (6.2–9.3) | 7 | 7.9 (5.2–10.3) | 0.323 |
| LH | 2 | 9.2 (6.7–11.7) | 3 | 4.8 (4.7–6.1) | 24 | 5.7 (3.7–10.1) | 113 | 5.4 (3.5–7.1) | 56 | 5.3 (3.7–6.4) | 8 | 4.9 (3.6–6) | 0.338 |
| Estradiol | 2 | 55.8 (51.5–68.2) | 3 | 47.3 (31.2–63.1) | 23 | 45.6 (38.2–76) | 108 | 40.6 (32.4–58.2) | 54 | 43.6 (34.3–57.9) | 7 | 55.7 (41.5–76) | 0.372 |
| AMH | 2 | 1.24 (0.94–1.55) | 2 | 2.49 (2.48–2.5) | 25 | 0.88 (0.55–3.35) | 120 | 1.86 (1.06–3.68) | 59 | 1.87 (1.14–3.16) | 8 | 1.37 (1.03–1.64) | 0.426 |
| Total oocyte number | 2 | 2.5 (2–3) | 3 | 9 (7–14) | 23 | 6 (2–14) | 120 | 7 (4–12) | 63 | 7 (5–12) | 8 | 4.5 (3.2–6) | 0.210 |
| MII oocyte number | 2 | 2 (2–2) | 2 | 6.5 (6–7) | 16 | 6 (2–15) | 92 | 6 (3–9) | 49 | 6 (4.5–9) | 5 | 5 (3–8.5) | 0.739 |
BMI body mass index, AFC antral follicle count, FSH follicle stimulating hormone, LH luteinizing hormone, AMH anti-Müllerian-hormone, MII oocytes mature oocytes.
aAge, mean ± standard deviation is presented
All other values are presented as median and 1st and 3rd quartile parenthesized
p values represent significance levels between the six evaluated FMR1 genotypes